GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Offer Oversubcribed

1 Jul 2014 10:47

RNS Number : 0577L
ViaLogy PLC
01 July 2014
 



1 July 2014

ViaLogy Plc

(the "Company")

 

Open Offer Oversubcribed

 

On 13 June 2014, ViaLogy Plc issued a circular to shareholders detailing that the Company had:

 

· conditionally acquired the entire issued share capital of Premaitha Health Limited ("Premaitha"), a molecular diagnostic company employing next generation DNA analysis technology to develop molecular diagnostic products intended to have a major beneficial impact on human health (www.premaitha.com);

 

· raised £6.5 million (before expenses) by means of the Placing; and

 

· intended to raise up to a further £0.7 million by means of the Open Offer.

 

The result of the Open Offer, which closed for acceptances at 11.00 a.m. on 30 June 2011, resulted in valid acceptances, including excess applications, being received in respect of 11,256,554 Open Offer Shares, representing a total of approximately 167 per cent. of those Open Offer Shares available and, as such, the Open Offer has been oversubscribed.

 

All valid applications in respect of basic entitlements under the Open Offer have been met in full and a scaling back exercise on a pro-rata basis to the number of excess Open Offer Shares applied for by Qualifying Shareholders under the Excess Application Facility has been undertaken.

 

The Company is therefore pleased to announce that it has raised gross proceeds of £7.2 million, comprising £0.7 million through the Open Offer and £6.5 million through the Placing.

 

The Proposals are subject to the approval of shareholders at a General Meeting to be held at 11.00 a.m. on 3 July 2014 at the offices of Panmure Gordon (UK) Limited, One New Change, London EC4M 9AF.

 

Adam Reynolds, Executive Chairman, commented:

"We are delighted by the support shown by our shareholders through the Open Offer. The net proceeds from the Placing and Open Offer will be used primarily to develop and commercialise the IONA® Test. "

 

This announcement should be read in conjunction with the full text of the Admission Document dated 13 June 2014. Defined terms in this announcement have the same meaning as those in the Admission Document.

 

 

For further information please contact:

ViaLogy Plc

Mark Collingbourne

 

 

+44 1620 810 183

 

Cairn Financial Advisers LLP

Nomad

Liam Murray

Avi Robinson

 

 

 

+44 20 7148 7900

 

Panmure Gordon (UK) Limited

Broker

Robert Naylor

Freddy Crossley

 

+44 20 7886 2500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKFLBBZDFZBBQ
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.